Gadolinium Dimeric Contrast Agent One-Pot Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for synthesizing gadolinium dimeric contrast agents for MRI require multiple isolation steps, harsh chemicals, and are not suitable for large-scale production, leading to reduced yield and efficiency.
Innovation Solution
A one-pot process that avoids intermediate isolation and uses milder solvents and reagents, optimizing the synthesis of gadolinium dimeric complexes by integrating steps such as alkylation, deprotection, and complexation in aqueous or aqueous-organic solvent mixtures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If multiple isolation steps are used in the synthesis process, then the purity of intermediates is improved, but the overall yield and productivity deteriorate
Solution Approach 1:
The patent combines multiple synthesis steps (alkylation, deprotection, complexation) into a one-pot process where intermediates are not isolated but carried forward in the reaction mixture. This merging of steps eliminates loss of material during isolation and significantly improves overall yield while maintaining product purity through selective reactions and final purification.
Solution Approach 2:
The patent performs deprotection of the DO3A derivative before the final complexation step, preparing the ligand in advance for subsequent gadolinium complexation. This preliminary action allows the deprotected ligand to be readily available for the final step without requiring isolation, improving process efficiency and yield.
2Manufacturing precision
If harsh chemicals such as TFA, TIPS and DCM are used, then the deprotection and purification steps are improved, but the safety and ease of operation deteriorate
Solution Approach 1:
The patent changes the chemical parameters by replacing harsh reagents (TFA, TIPS, DCM) with milder alternatives (aqueous base, water-soluble solvents). This parameter change maintains deprotection efficiency through alternative chemistry while dramatically improving safety and ease of handling for industrial operations.
Solution Approach 2:
The patent uses water-soluble reagents and solvents that can be easily disposed of through aqueous workup, replacing expensive and hazardous solvents like DCM that require special handling and disposal procedures. This makes the process more economical and safer for industrial scale-up.
3Manufacturing precision
If harsh chemicals such as TFA, TIPS and DCM are used, then the deprotection and purification steps are improved, but the device complexity and cost increase
Solution Approach 1:
The patent changes from acidic deprotection conditions (TFA) to basic or neutral conditions (aqueous base, water), eliminating the need for corrosion-resistant equipment and special material selections. This parameter change simplifies device requirements and reduces capital costs for industrial implementation.
4Manufacturing precision
If multiple isolation and purification steps are used, then the purity of the final product is improved, but the time consumption and productivity deteriorate
Solution Approach 1:
The patent merges synthesis, deprotection, and complexation into a single continuous process without intermediate isolations. This dramatically reduces process time while maintaining purity through selective chemistry and a single final purification step using Amberchrome resin, which efficiently separates the final complex from impurities.
Solution Approach 2:
The patent maintains continuous useful action by carrying reaction mixtures directly from one step to the next without interruption for isolation. The reaction components remain in solution throughout, allowing continuous transformation and minimizing idle time, thus improving productivity while achieving high purity through the final resin purification.
Data Source
AI summary
The invention relates to a process for the preparation of the gadolinium dimeric contrast agent [p-[1-[bis[2-(hydroxy-KO)-3-[4,7,10-tris[(carboxy-KO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-K/V1,K/V4,K/V7,K/V10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex. Such process includes preparation steps carried out one-pot and without isolation of the obtained intermediates. The gadolinium dimeric contrast agent can be for use in diagnostic imaging, in particular in Magnetic resonance Imaging (MRI).